OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 51.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,284 shares of the biopharmaceutical company’s stock after selling 23,985 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Ultragenyx Pharmaceutical were worth $937,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth $35,000. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $42,000. Van ECK Associates Corp grew its stake in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 273 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $84,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 1.9%

Shares of NASDAQ RARE opened at $35.40 on Wednesday. The firm’s 50-day moving average price is $36.67 and its two-hundred day moving average price is $42.11. Ultragenyx Pharmaceutical Inc. has a 52-week low of $29.59 and a 52-week high of $60.37. The stock has a market capitalization of $3.35 billion, a P/E ratio of -5.58 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same quarter last year, the company posted ($2.03) EPS. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on RARE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler reduced their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Monday, March 17th. JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $90.93.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 2,990 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at approximately $2,358,014.08. This represents a 5.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 1,785 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares of the company’s stock, valued at $4,289,227.60. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 125,405 shares of company stock worth $5,285,169. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.